Advertisement

Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy

Published:October 05, 2018DOI:https://doi.org/10.1016/j.oooo.2018.09.012

      Objective

      Osteonecrosis of the jaw (ONJ) is commonly associated with antiresorptive therapy. There have been numerous reports of ONJ unrelated to antiresorptive therapy (ONJuat), confounding risk assessment. This study aimed to determine if ONJuat is associated with one or more particular comorbidities.

      Study Design

      This was a retrospective case-control study of patients with ONJuat and delayed healing (DH). Each case was matched for patient age and gender, as well as location of ONJuat or DH lesion to a control patient who had a history of dentoalveolar surgery with uneventful healing and no history of antiresorptive therapy. Comorbidity data included medical conditions and smoking.

      Results

      Of the 92 patients identified, 67 (73%) met the criteria for ONJuat and 25 (27%) for DH. The most common trigger for ONJ and DH was extraction (50%). The presence of any comorbidity (i.e., at least 1) was more prevalent in ONJuat than among controls (P = .04), and there were more comorbidities in patients with ONJuat and DH than in controls [M(SD) = 1.94 (1.2) and 2.0 (1.3) vs 1.26 (0.89); both P < .001].

      Conclusions

      ONJ and DH are not limited to patients with a history of antiresorptive therapy. More comorbidities may signal increased risk for ONJuat and DH.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Leder B
        • Tsai J
        • Jiang L
        • Lee H
        Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-up).
        Bone. 2017; 98: 54-58
        • Lipton A
        • Fizazi K
        • Stopeck A
        • et al.
        Effect of denosumab versus zolendronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
        Eur J Cancer. 2016; 53: 75-83
        • Brozek W
        • Reichardt B
        • Zwerina J
        • Dimai H
        • Klaushofer K
        • Zwettler E
        Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
        Osteoporos Int. 2016; 27: 387-396
        • Peddi P
        • Lopez-Olivo M
        • Pratt G
        • Suarez-Almazor M
        Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.
        Cancer Treatment Reviews. 2013; 39: 97-104
        • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
        Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.
        Lancet. 2015; 386: 1353-1361
        • Zhang X
        • Hamadeh I
        • Song S
        • et al.
        Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
        J Bone Miner Res. 2015; 31: 336-340
        • Hamadeh I
        • Ngwa B
        • Gong Y
        Drug induced osteonecrosis of the jaw.
        Cancer Treat Rev. 2015; 41: 455-464
        • Ruggiero S
        • Dodson T
        • Fantasia J
        • et al.
        AAOMS position paper: medication-related osteonecrosis of the jaw—2014 Update.
        Am Assoc Oral Maxillofac Surg. 2014; 72: 1938-1956
        • Ruggiero S
        Diagnosis and staging of medication-related osteonecrosis of the jaw.
        Oral Maxillofac Surg Clin N Am. 2015; 27: 479-487
        • Marx R
        • Pamidronate
        (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.
        J Oral Maxillofac Surg. 2003; 61: 1115-1117
        • Khan A
        • Morrison A
        • Hanley D
        • et al.
        Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
        J Bone Miner Res. 2015; 30: 3-23
        • Migliorati C
        • Siegel M
        • Elting L
        Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
        Lancet Oncol. 2006; 7: 508-514
        • Miksad R
        • Lai K
        • Dodson T
        • et al.
        Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.
        Oncologist. 2011; 16: 121-132
        • Otto S
        • Schreyer C
        • Hafner S
        • et al.
        Bisphosphonate-related osteonecrosis of the jaw—characteristics, risk factors, clinical features, localization and impact on oncological treatment.
        J Craniomaxillofac Surg. 2012; 40: 303-309
        • Talreja D
        Importance of antiresorptive therapies for patients with bone metastases from solid tumors.
        Cancer Manage Res. 2012; 4: 287-297
        • Khosla S
        • Shane E
        A crisis in the treatment of osteoporosis.
        J Bone Miner Res. 2016; 31: 1485-1487
        • Adamo V
        • Caristi N
        • Sacca M
        • et al.
        Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients.
        Expert Opin Pharmacother. 2008; 9: 1351-1361
        • Kumar V
        • Pass B
        • Guttenberg S
        • et al.
        Bisphosphonate-related osteonecrosis of the jaws: a report of three cases demonstrating variability in outcomes and morbidity.
        J Am Dent Assoc. 2007; 138: 602-609
        • Marx R
        • Sawatari Y
        • Fortin M
        • Broumand V
        Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
        J Oral Maxillofac Surg. 2005; 63: 1567-1575
        • Otto S
        • Hafner S
        • Mast G
        • et al.
        Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?.
        J Oral Maxillofac Surg. 2010; 68: 1158-1161
        • Morris P
        • Hudis C
        • Carrasquillo J
        • Larson S
        • Grewal R
        • Van Posnak C
        Bone scans, bisphosphonates, and a lack of acute changes within the mandible.
        J Oral Maxillofac Surg. 2011; 69: 114-119
        • Weiss H
        • Pfaar U
        • Schweitzer A
        • Wiegand H
        • Skerjanec A
        • Schran H
        Biodistribution and plasma protein binding of zoledronic acid.
        Drug Metab Dispos. 2008; 36: 2043-2049
        • Bauss F
        • Pfister T
        • Papapoulos S
        Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.
        J Bone Miner Metab. 2008; 26: 406-408
        • Ristow O
        • Gerngrofs C
        • Schwaiger M
        • et al.
        Is bone turnover of jawbone and its possible over suppression by bisphosphonates of etiologic importance in pathogenesis of bisphosphonate-related osteonecrosis?.
        J Oral Maxillofac Surg. 2014; 72: 903-910
        • Ristow O
        • Gerngro C
        • Schwaiger M
        • et al.
        Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
        Br J Oral Maxillofac Surg. 2014; 52: 308-313
        • Van den Wyngaert T
        • Huizing M
        • Vermorken J
        Osteonecrosis of the jaw related to the use of bisphosphonates.
        Curr Opin Oncol. 2007; 19: 315-322
        • Woo S
        • Hellstein J
        • Kalmar J
        Systematic review: bisphosphonates and osteonecrosis of the jaws.
        Ann Intern Med. 2006; 144: 753-761
        • Baron R
        • Ferrari S
        • Graham R
        • Russell R
        Denosumab and bisphosphonates: different mechanisms of action and effects.
        Bone. 2011; 48: 677-692
        • Charopoulos I
        • Orme S
        • Giannoudis P
        The role and efficacy of denosumab in the treatment of osteoporosis: an update.
        Expert Opin Drug Saf. 2011; 10: 205-217
        • Cassoni A
        • Romeo U
        • Terenzi V
        • et al.
        Adalimumab: another medication related to osteonecrosis of the jaws?.
        Case Rep Dent. 2016; 20162856926
        • Kos M
        • Brusco D
        • Kuebler J
        • Engelke W
        Clinical comparison of patients with osteonecrosis of the jaw, with and without a history of bisphosphonates administration.
        Int J Oral Maxillofac Surg. 2010; 39: 1097-1102
        • Almazrooa S
        • Woo S
        Bisphosphonate and non–bisphosphonate-associated osteonecrosis of the jaw: a review.
        JADA. 2009; 140: 864-875
        • Infante-Cossio P
        • Lopez-Martin J
        • Gonzalex-Cardero E
        • Martinez-de-Fuentes R
        • Casas-Fernandez-Tejerina A
        Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures.
        J Oral Maxillofac Surg. 2012; 70: 1587-1592
        • Baur D
        • Weber J
        • Collette D
        • Dhaliwal H
        • Queresby F
        Osteonecrosis of the jaws unrelated to bisphosphonate exposure: a series of 4 cases.
        J Oral Maxillofac Surg. 2012; 70: 2802-2808
        • Lenz J
        • Steiner-Krammer B
        • Schmidt W
        • Fietkau R
        • Mueller P
        • Gundlach K
        Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?.
        J Craniomaxillofac Surg. 2005; 33: 395-403
        • Hopp R
        • Pucci J
        • Santos-Silva A
        • Jorge J
        Osteonecrosis after administration of intravitreous bevacizumab.
        J Oral Maxillofac Surg. 2012; 70: 632-635
        • Fleissig Y
        • Regev E
        • Lehman H
        Sunitinib related osteonecrosis of jaw: a case report.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113: e1-e3
        • DeSesa C
        • Appugounder S
        • Haberland C
        • Johnson M
        Osteonecrosis of the jaw in association with chemotherapy in the setting of cutaneous T-cell lymphoma.
        J Oral Maxillofac Surg. 2016; 74: 292-301
        • Yamamoto D
        • Tsubota Y
        • Utsunomiya T
        • et al.
        Osteonecrosis of the jaw associated with everolimus: a case report.
        Mol Clin Oncol. 2017; 6: 255-257
        • Zarringhalam P
        • Brizman E
        • Shakib K
        Medication-related osteonecrosis of the jaw associated with aflibercept.
        Br J Oral Maxillofac Surg. 2017; 55: 314-315
        • Aghaloo T
        • Tetradis S
        Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases.
        J Oral Maxillofac Surg. 2017; 75: 129-142
        • Furudate K
        • Satake A
        • Narita N
        • Kobayashi W
        Methotrexate-related lymphoproliferative disorder in patients with osteonecrosis of the jaw: a 3-case report and literature review.
        J Oral Maxillofac Surg. 2018; 76: 97-111
        • Keribin P
        • Guerrot D
        • Jardin F
        • Moizan H
        Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report.
        J Oral Maxillofac Surg. 2017; 75: 2599-2605
        • Jadu F
        • Lee L
        • Pharoah M
        • Reece D
        • Wang L
        A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients.
        Ann Oncol. 2007; 18: 2015-2019
        • Vermeer J
        • Renders G
        • Everts V
        Osteonecrosis of the jaw—a bone site-specific effect of bisphosphonates.
        Curr Osteoporos Rep. 2016; 14: 219-225
        • McGowan K
        • McGowan T
        • Invanovski S
        Risk factors for medication-related osteonecrosis of the jaws: a systematic review.
        Oral Dis. 2017; 00: 1-10
        • Hess L
        • Jeter J
        • Benham-Hutchins M
        • Alberts D
        Factors associated with osteonecrosis of the jaw among bisphosphonate users.
        Am J Med. 2008; 121: 475-483
        • Thumbigere-Math V
        • Tu L
        • Huckabay S
        • et al.
        A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates.
        Am J Clin Oncol. 2012; 35: 286-392
        • Zavras A.
        The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future.
        Ann N Y Acad Sci. 2011; 1218: 55-61
        • Wessel J
        • Dodson T
        • Zavras A
        Zolendronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study.
        J Oral Maxillofac Surg. 2008; 66: 625-631
        • Khamaisi M
        • Regev E
        • Yarom N
        • et al.
        Possible association between diabetes and bisphosphonate-related jaw osteonecrosis.
        J Clin Endocrinol Metab. 2007; 92: 1172-1175
        • Hutchinson M
        • O'Ryan F
        • Chavez V
        • et al.
        Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure.
        J Oral Maxillofac Surg. 2010; 68: 2232-2240
        • Ruggiero S.
        Bisphosphonate-related osteonecrosis of the jaw: an overview.
        Ann N Y Acad Sci. 2011; 1218: 38-46
        • Sedghizadeh P
        • Kumar S
        • Gorur A
        • Schaudinn C
        • Shuler C
        • Costerton J
        Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy.
        J Am Dent Assoc. 2009; 140: 1259-1265
        • Bedogni A
        • Blandamura S
        • Lokmic Z
        • et al.
        Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 358-364
        • Pires F
        • Miranda A
        • Cardoso E
        • et al.
        Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy.
        Oral Dis. 2005; 11: 365-369
        • Cho Y
        • Yoon H
        • Lee J
        • Hong S
        • Hong S
        Histopathological features of bisphosphonate-associated osteonecrosis: findings in patients treated with partial mandibulectomies.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114: 785-791
        • Shuster A
        • Reiser V
        • Trejo L
        • Lanculovici C
        • Kleinman S
        • Kaplan I
        Comparison of the histologic characteristics of osteomyelitis, medication-related osteonecrosis of the jaw and osteoradionecrosis.
        Int J Oral Maxillofac Surg. 2018; ([In Press])
        • Bagan J
        • Hens-Aumente E
        • Leopoldo-Rodado M
        • Poveda-Roda R
        • Bagan L
        Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases.
        Oral Oncol. 2012; 48: 753-757
        • Fedele S
        • Porter S
        • A'Aiuto F
        • et al.
        Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series.
        Am J Med. 2010; 123: 1060-1064
        • Politis C
        • Schoenaers J
        • Jacobs R
        • Agbaje J
        Wound healing problems in the mouth.
        Front Physiol. 2016; 7: 507
        • Parthasarathi K
        • Smit A
        • Chandu A
        Factors affecting incidence of dry socket: a prospective community-based study.
        J Oral Maxillofac Surg. 2011; 69: 1880-1884
        • Blum I.
        Contemporary views on dry socket (alveolar osteitis): a clinical appraisal of standardization, aetiopathogenesis and management: a critical review.
        Int J Oral Maxillofac Surg. 2002; 31: 309-317
        • Paek S
        • Park W
        • Shin H
        • Choi M
        • Kwon K
        • Choi E
        Diseases having an influence on inhibition of angiogenesis as risk factors of osteonecrosis of the jaw.
        J Korean Assoc Oral Maxillofac Surg. 2016; 42: 271-277
        • Schwartz H.
        Osteonecrosis of the jaws: a complication of cancer chemotherapy.
        Head Neck Surg. 1982; 4: 251-253
        • Almazrooa S
        • Chen K
        • Nascimben L
        • Woo S
        • Treister N
        Osteonecrosis of the mandible after laryngoscopy and endotracheal tube placement.
        Anesth Analg. 2010; 111: 437-441
        • Henien M
        • Carey B
        • Hullah E
        • Sproat C
        • Patel V
        Methotrexate-associated osteonecrosis of the jaw: a report of two cases.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2017; 124: e283-e287
        • Kalantzis A
        • Marshman Z
        • Falconer D
        • Morgan P
        • Odell E
        Oral effects of low-dose methotrexate treatment.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100: 52-62
        • Patil P
        • Bhadani P
        Extensive maxillary necrosis following tooth extraction.
        J Oral Maxillofac Surg. 2011; 69: 2387-2391
        • Won A
        • Boddu P
        • Otun A
        • Aponte-Wesson R
        • Chambers M
        Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May 30; (pii: S2212-4403(18)30952-0[Epub ahead of print])https://doi.org/10.1016/j.oooo.2018.05.008
        • Jain M
        • Manjunath K
        • Jagadish S
        Unusual oral complications of herpes zoster infection: report of a case and review of the literature.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 110: e37-e41
        • Seyer B
        • Gist W
        • Muller S
        Aggressive destructive midfacial lesion from cocaine abuse.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002; 94: 465-470
        • Maddur M
        • Miossec P
        • Kaveri S
        • Bayry J
        Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.
        Am J Pathol. 2012; 181: 8-18
        • Zhang Q
        • Atsuta I
        • Liu S
        • et al.
        IL-17-mediated M1/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws.
        Clin Cancer Res. 2013; 19: 3176-3188
        • Guo S
        • DiPietro L
        Factors affecting wound healing.
        J Dent Res. 2010; 89: 219-229
        • Hupp J
        • Ellis E
        • Tucker M
        Contemporary Oral and Maxillofacial Surgery.
        Elsevier, St. Louis, MO2014 (ed 6)
        • Izadi K
        • Ganchi P
        Chronic wounds.
        Clin Plastic Surg. 2005; 32: 209-222
        • Saia G
        • Blandamura S
        • Bettini G
        • et al.
        Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction.
        J Oral Maxillofac Surg. 2010; 68: 797-804
        • Chiapinotto B
        • Salum F
        • Figueiredo M
        • Cherubini K
        Important aspects regarding the role of microorganisms in bisphosphonate-related osteonecrosis of the jaws.
        Arch Oral Biol. 2014; 59: 790-799
        • Katsarelis H
        • Shah N
        • Dhariwal D
        • Pazianas M
        Infection and medication-related osteonecrosis of the jaw.
        Crit Rev Oral Biol Med. 2015; 94: 534-539
        • Otto S
        • Pautke C
        • Opelz C
        • et al.
        Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
        J Oral Maxillofac Surg. 2010; 68: 2837-2845
        • Tsurushima H
        • Kukuryo S
        • Sakaguchi O
        • Tanaka J
        Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats.
        Int J Oral Maxillofac Surg. 2013; 42: 1481-1487
        • Reid I.
        Osteonecrosis of the jaw—who gets it, and why?.
        Bone. 2009; 44: 4-10
        • de Molon R
        • Cheong S
        • Bezouglaia O
        • et al.
        Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.
        Bone. 2014; 68: 11-19
        • Peer A
        • Khamaisi M
        Diabetes as a risk factor for medication-related osteonecrosis of the jaw.
        J Dent Res. 2015; 94: 252-260
        • Pozzi S
        • Marcheselli R
        • Sacchi S
        • et al.
        Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and evaluation of its frequency in multiple myeloma patients.
        Leuk Lymphoma. 2007; 48: 56-64
        • Yarom N
        • Yahalom R
        • Shoshani Y
        • Hamed W
        • Regev E
        • Elad S
        Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
        Osteoporos Int. 2007; 18: 1363-1370
        • Khosla S
        • Burr D
        • Cauley J
        • et al.
        Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.
        J Bone Miner Res. 2007; 22: 1479-1491
        • Hoefert S
        • Eufinger H
        Relevance of a prolonged preoperative antibiotic regime in the treatment of bisphosphonate-related osteonecrosis of the jaw.
        J Oral Maxillofac Surg. 2011; 69: 362-380
        • Baur D
        • Altay M
        • Flores-Hidalgo A
        • Ort Y
        • Quereshy F
        Chronic osteomyelitis of the mandible: diagnosis and management—an institution's experience over 7 years.
        J Oral Maxillofac Surg. 2015; 73: 655-665
        • Valko M
        • Leibfritz D
        • Moncol J
        • Cronin M
        • Mazur M
        • Telser J
        Free radicals and antioxidants in normal physiologic functions and human disease.
        Int J Biochem Cell Biol. 2007; 39: 44-84
        • Bhat A
        • Dar K
        • Anees S
        • et al.
        Oxidative stress, mitochondrial dysfunction and neurogenerative diseases: a mechanistic insight.
        Biomed Pharm. 2015; 74: 101-110
        • Pham-Huy L
        • He H
        • Pham-Huy C
        Free radicals, antioxidants in disease and health.
        Int J Biomed Sci. 2008; 4: 89-96
        • Denu R
        • Hematti P
        Effects of oxidative stress on mesenchymal stem cell biology.
        Oxid Med Cell Longev. 2016; 20162989076
        • Schafer M
        • Werner S
        Oxidative stress in normal and impaired wound repair.
        Pharmacol Res. 2008; 58: 165-171
        • Ponugoti B
        • Xu F
        • Zhang C
        • Tian C
        • Pacios S
        • Graves D
        FOXO1 promotes wound healing through the up-regulation of TGF-β1 and prevention of oxidative stress.
        J Cell Biol. 2013; 203: 327-343
        • Wlaschek M
        • Scharffetter-Kochanek K
        Oxidative stress in chronic venous leg ulcers.
        Wound Rep Reg. 2005; 13: 452-461
        • Rosenbaum M
        • Miyazaki K
        • Graham L
        Hypercholesterolemia and oxidative stress inhibit endothelial cell healing after arterial injury.
        J Vascular Surg. 2012; 55: 489-496
        • Xiao L
        • Miwa N
        Hydrogen-rich water achieves cytoprotection from oxidative stress injury in human gingival fibroblasts in culture or 3-D-tissue equivalents, and wound-healing promotion, together with ROS-scavenging and relief from glutathione diminishment.
        Hum Cell. 2017; 30: 72-87
        • Firat E
        • Dag A
        • Gunay A
        • et al.
        The effects of low-level laser therapy on palatal mucoperiosteal wound healing and oxidative stress status in experimental diabetic rats.
        Photomed Laser Surg. 2013; 31: 315-321
        • Callaway D
        • Jiang J
        Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases.
        J Bone Miner Metab. 2015; 33: 359-370
        • Domazetovic V
        • Marcucci G
        • Iantomasi T
        • Brandi M
        • Vincenzini M
        Oxidative stress in bone remodeling: role of antioxidants.
        Clin Cases Mineral Bone Metab. 2017; 14: 209-216
        • Chapple I
        • Matthews J
        The role of reactive oxygen and antioxidant species in periodontal tissue destruction.
        Periodontology. 2007; 43: 160-232
        • Thumbigere-Math V
        • Michalowicz B
        • Hodges J
        • et al.
        Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw.
        J Periodontol. 2014; 85: 226-233
        • Bullon P
        • Morillo J
        • Ramirez-Tortosa M
        • Quiles J
        • Newman H
        • Battino M
        Metabolic syndrome and periodontitis: is oxidative stress a common link?.
        Crit Rev Oral Biol Med. 2009; 88: 503-518
        • Tamaki N
        • Hayashida H
        • Fukui M
        • et al.
        Oxidative stress and antibody levels to periodontal bacteria in adults: the Nagasaki Islands study.
        Oral Diseases. 2014; 20: e49-e56
        • Levy Y
        Oxidative stress, antioxidants and periodontal disease.
        Arch Oral Biol. 2015; 60: 1461-1462
        • Ebersole J
        • Cappelli D
        Acute-phase reactants in infections and inflammatory diseases.
        Periodontology. 2000; 23: 19-49
        • Lugrin J
        • Rosenblatt-Velin N
        • Parapanov R
        • Liaudet L
        The role of oxidative stress during inflammatory processes.
        Biol Chem. 2014; 395: 203-230
        • Bagan J
        • Saez G
        • Tormos M
        • et al.
        Oxidative stress in bisphosphonate-related osteonecrosis of the jaws.
        J Oral Pathol Med. 2014; 43: 371-377
        • Chapple I
        Potential mechanisms underpinning the nutritional modulation of periodontal inflammation.
        J Am Dent Assoc. 2009; 140: 178-184
        • Chandel N
        • Tuveson D
        The promise and perils of antioxidants for cancer patients.
        N Engl J Med. 2014; 371: 177-178
        • Bhattacharyya A
        • Chattopadhyay R
        • Mitra S
        • Crowe S
        Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.
        Physiol Rev. 2014; 94: 354-392
        • Diniz B
        • Mendes-Silva A
        • Silva L
        • et al.
        Oxidative stress markers imbalance in late-life depression.
        J Psychiatric Res. 2018; 102: 29-33
        • Napenas J
        • Brennan M
        • Bahrani-Mougeot F
        • Fox P
        • Lockhart P
        Relationship between mucositis and changes in oral microflora during cancer chemotherapy.
        Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103: 48-59
        • Epstein J
        • Chow A
        Oral complications associated with immunosuppression and cancer therapies.
        Infect Dis Clin N Am. 1999; 13: 901-923
        • Meurman J
        • Pyrhonen S
        • Teerenhovi L
        • Lindqvist C
        Oral sources of septicaemia in patients with malignancies.
        Oral Oncol. 1997; 33: 389-397
        • Overholser C
        • Peterson D
        • Williams L
        • Schimpff S
        Periodontal infection in patients with acute nonlymphocytic leukemia: prevalence of acute exacerbations.
        Arch Intern Med. 1982; 142: 551-554
        • Raber-Durlacher J
        • Epstein J
        • Raber J
        • et al.
        Periodontal infection in cancer patients treated with high-dose chemotherapy.
        Support Care Cancer. 2002; 10: 466-473
        • Santos-Silva A
        • Belizario Rosa G
        • De Castro G
        • Brito Dias R
        • Prado Ribeiro A
        • Bianca Brandao T
        Osteonecrosis of the mandible associated with bevacizumab therapy.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115: e32-e36
        • Magremanne M
        • Lahon M
        • De Ceulaer J
        • Reychler H
        Unusual bevacizumab-related complication of an oral infection.
        J Oral Maxillofac Surg. 2013; 71: 53-55
        • Bettini G
        • Blandamura S
        • Saia G
        • Bedogni A
        Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.
        BMJ Case Rep. 2012 Oct 22; (2012. pii: bcr2012007284)https://doi.org/10.1136/bcr-2012-007284
        • Papageorgiou S
        • Hagner M
        • Nogueira A
        • Franke A
        • Jager A
        • Deschner J
        Inflammatory bowel disease and oral health: systematic review and a meta-analysis.
        J Clin Periodontol. 2017; 44: 382-393
        • Piras V
        • Usai P
        • Mezzenza S
        • et al.
        Prevalence of apical periodontitis in patients with inflammatory bowel diseases: a retrospective clinical study.
        J Endod. 2017; 43: 389-394
        • Peruzzo D
        • Benatti B
        • Ambrosano G
        • et al.
        A systematic review of stress and psychological factors as possible risk factors for periodontal disease.
        J Periodontol. 2007; 78: 1491-1504
        • Glaser R
        • Kiecolt-Glaser J
        Stress-induced immune dysfunction implications for health.
        Nat Rev Microbiol. 2005; 5: 243-251
        • Lazarovici T
        • Yahalom R
        • Taicher S
        • Elad S
        • Hardan I
        • Yarom N
        Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients.
        J Oral Maxillofac Surg. 2009; 67: 850-855
        • Vescovi P
        • Campisi G
        • Fusco V
        • et al.
        Surgery-triggered and non–surgery-triggered bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 567 cases in an Italian multicenter study.
        Oral Oncol. 2011; 47: 191-194
        • Uyanne J
        • Calhoun C
        • Le A
        Antiresorptive drug-related osteonecrosis of the jaw.
        Dent Clin N Am. 2014; 58: 369-384
        • Bagan J
        • Peydro A
        • Calvo J
        • Leopoldo M
        • Jimenez Y
        • Bagan L
        Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
        Oral Dis. 2016; 22: 324-329
        • Schiodt M
        • Vadhan-Raj S
        • Chambers M
        • et al.
        A multicenter case registry of medication-related osteonecrosis of the jaw in patients with advanced cancer.
        Support Care Cancer. 2018; 26: 1905-1915
        • Watters A
        • Hansen H
        • Williams T
        • et al.
        Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115: 192-200
        • Dodson T
        Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
        J Oral Maxillofac Surg. 2009; 67: 44-52
        • Bilezikian J.
        Osteonecrosis of the jaw—do bisphosphonates pose a risk?.
        N Engl J Med. 2006; 355: 2278-2281
        • Allen M
        • Burr D
        The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.
        J Oral Maxillofac Surg. 2009; 67: 61-70
        • Hankey G
        Osteomyelitis (necrosis) of the jaws—its pathology and treatment.
        Br Dent J. 1938; 65: 550-559
        • Parker D.
        Osteomyelitis of the mandible: report of a case.
        J Oral Surg. 1949; 7: 69-71
        • Peters E
        • Lovas G
        • Wysocki G
        Lingual mandibular sequestration and ulceration.
        Oral Surg Oral Med Oral Pathol. 1993; 75: 739-743
        • Adekeye E
        • Cornah J
        Osteomyelitis of the jaws: a review of 141 cases.
        Br J Oral Maxillofac Surg. 1985; 23: 24-35
        • Ortega K
        • Rezende N
        • Lotufo M
        • Magalhaes H
        Mandibular lesion in an HIV-positive patient.
        J Oral Maxillofac Surg. 2008; 66: 2140-2144
        • Coleman R
        • Cook R
        • Hirsh V
        • Major P
        • Lipton A
        Zoledronic acid use in cancer patients.
        Cancer. 2011; 117: 11-23
        • Kajizono M
        • Sada H
        • Sugiura Y
        • et al.
        Incidence and risk factors for osteonecrosis of the jaw in advanced cancer patients after treatment with zoledronic acid or denosumab: a retrospective cohort study.
        Biol Pharm Bull. 2015; 38: 1850-1855
        • Carlson E
        • Schlott B
        Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned.
        Oral Maxillofac Surg Clin N Am. 2014; 26: 171-191
        • Coviello V
        • Stevens M
        Contemporary concepts in the treatment of chronic osteomyelitis.
        Oral Maxillofac Surg Clin N Am. 2007; 19: 523-534
        • Koorbusch G
        • Deatherage J
        • Cure J
        How can we diagnose and treat osteomyelitis of the jaws as early as possible?.
        Oral Maxillofac Surg Clin N Am. 2011; 23: 557-567